Regencell Bioscience (NASDAQ:RGC) Stock Price Down 3.9% – Time to Sell?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) were down 3.9% on Friday . The company traded as low as $5.22 and last traded at $5.23. Approximately 93,399 shares were traded during trading, a decline of 70% from the average session volume of 307,115 shares. The stock had previously closed at $5.44.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RGC. Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Down 2.6%

The business has a fifty day moving average of $6.92 and a 200-day moving average of $19.79.

Institutional Investors Weigh In On Regencell Bioscience

Hedge funds have recently made changes to their positions in the company. Vident Advisory LLC raised its holdings in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares in the last quarter. Squarepoint Ops LLC bought a new position in Regencell Bioscience during the 2nd quarter worth about $1,701,000. BNP Paribas Financial Markets bought a new position in Regencell Bioscience during the 2nd quarter worth about $768,000. XTX Topco Ltd purchased a new position in Regencell Bioscience during the 3rd quarter valued at about $598,000. Finally, Hudson Bay Capital Management LP purchased a new position in Regencell Bioscience during the 4th quarter valued at about $275,000. 0.13% of the stock is currently owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.